Journal of Thoracic Oncology

Hanna, Nasser

2006 Journal of Thoracic Oncology

doi:

Geraci, Mark W.

2006 Journal of Thoracic Oncology

doi:

Wong, Maria P.

2006 Journal of Thoracic Oncology

doi:

Four new lung adenocarcinoma cell lines were established from patients with different clinical characteristics. These characterized cell lines and their gene expression profiles will provide resources for studies of lung cancer biology and in vitro chemotherapeutic drug study.

Jablons, David M.

2006 Journal of Thoracic Oncology

doi:

Diagnosis of NSCLC by cytology alone results in significant misclassification of BAC, most commonly as adenocarcinoma or undifferentiated NSCLC. Because patients with BAC respond differently to certain treatments such as endothelial growth factor receptor inhibitors and surgical resection of multifocal lung cancer, misclassification of BAC may have important therapeutic implications.

Yoshimoto, Kentaro

2006 Journal of Thoracic Oncology

doi:

For mediastinal lymph node biopsy, both the largest and the second largest node at each station should be sampled, especially in adenocarcinoma. If only the largest lymph node is selected, false-negative results will occur at a rate of about 10%.

Gould, Michael K.

2006 Journal of Thoracic Oncology

doi:

Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.

Pate, James W.

2006 Journal of Thoracic Oncology

doi:

Survival during 10-year observation was similar for patients with pulmonary insufficiency treated by wedge resection to that of patients receiving standard resection in this single-institution consecutive cohort.

Lee, Jin Soo

2006 Journal of Thoracic Oncology

doi:

Gefitinib showed very promising antitumor activity and survival outcome in Korean never-smokers with adenocarcinoma of the lung. It seems to be a good alternative to standard chemotherapy as a first-line therapy for this subgroup.

Govindan, Ramaswamy

2006 Journal of Thoracic Oncology

doi:

The combination of carboplatin and irinotecan is an active combination in NSCLC, with response rates comparable with other platinum-containing doublets. Further studies with irinotecan should incorporate prospective pharmacogenomic analysis to identify markers for response and toxicity.

Nukiwa, Toshihiro

2006 Journal of Thoracic Oncology

doi:

Biweekly docetaxel plus carboplatin has a similar efficacy and lower toxicity compared with a standard triweekly regimen of docetaxel plus carboplatin, which is a suitable regimen for outpatients, including elderly patients.